Antonius Schuh

Dr. Antonius Schuh is a certified pharmacist with a Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany. He has more than 20 years of executive leadership experience in the biotechnology, healthcare, and life sciences industries and has served as CEO of five life sciences companies, including Sequenom (NASDAQ: SQNM), where he entered his CEO position at the seed stage leading the company to a market valuation of over $1B through a successful IPO in NASDAQ (2006-2008); as well as Arcturus Bioscience, AviaraDx (now bioTheranostics), Sorrento Therapeutics (NASDAQ: SRNE), and Trovagene (NASDAQ: TROV). In each case, Dr. Schuh developed the company’s strategy based on a focused value proposition, oversaw the execution of such strategy, and secured funding to achieve transforming milestones, including multiple product launches. He delivered significant returns for investors at the exit, public offering, or acquisition.

As Chairman of the BoD, Dr. Schuh is the architect of Omnix's execution and milestone-driven strategy to achieve the company’s future goals.